Annonce • Apr 01

ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile

ORIC Pharmaceuticals, Inc. announced a rinzimetostat (ORIC-944) program update and potential best-in-disease efficacy and safety data from the Phase 1b trial of once daily rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate (abiraterone). Rinzimetostat 400 mg once daily was selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in the first half of 2026. At a median follow-up of approximately 5 months, landmark 5-month rPFS of 84% is consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC. Highly differentiated, potential best-in-disease safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and far fewer treatment modifications than competitor regimens. Patients were previously treated with a median of two prior lines of therapy, including abiraterone, up to one prior line of chemotherapy, and a variety of other approved and investigational treatment regimens. 18 patients were treated with 400 mg of rinzimetostat once daily and 15 patients were treated with 600 mg of rinzimetostat once daily, both in combination with the standard dose of darolutamide at 600 mg twice daily. At the 400 mg dose, rinzimetostat in combination with darolutamide continues to be well tolerated and demonstrates a safety profile supportive of long-term administration and sustained patient adherence. As of the January 16, 2026 data cutoff, the vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity and consistent with PRC2 and AR inhibition. The most common TRAEs were fatigue (39%; 17% Grade 1 and 22% Grade 2), diarrhea (22%; 17% Grade 1 and 6% Grade 2) and nausea (22%; all Grade 1). A single Grade 3 TRAE was observed, and no Grade 4 or 5 AEs were attributed to rinzimetostat or darolutamide. Dose modifications were rare (one interruption and one discontinuation), with no dose reductions required. The 600 mg dose of rinzimetostat in combination with darolutamide was associated with a modestly higher rate of adverse events and dose modifications. In a broader dataset of post-ARPI (androgen receptor pathway inhibitor) patients (n=72, inclusive of the post-abiraterone patients), the safety and tolerability profile was consistent with the post-abiraterone cohort. To support the selection of the recommended Phase 3 dose in accordance with the FDA's Project Optimus initiative, the company conducted a comprehensive exposure-response (E-R) analysis in over 100 patients across both the single-agent and combination data evaluating the relationship between rinzimetostat drug exposure versus efficacy and safety outcomes. The analysis demonstrated that 400 mg and 600 mg once daily provided comparable efficacy. In contrast, the E-R analysis identified statistically significant relationships between higher drug exposure and toxicities as well as increased rates of treatment modifications, clearly favoring the 400 mg dose on the basis of safety. Based on these findings 400 mg once daily in combination with darolutamide has been selected as the RP3D for rinzimetostat. As of March 6, 2026, radiographic progression-free survival (rPFS) was assessed in 18 efficacy-evaluable patients. PSA responses were assessed in a subset of 15 patients with at least one post-baseline assessment as of the January 16, 2026 clinical cutoff. ctDNA molecular response was evaluated in 14 patients with detectable ctDNA at baseline. Early efficacy data, including landmark rPFS rates, PSA reductions and ctDNA responses, are suggestive of meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies. Rinzimetostat 400 mg once daily in combination with darolutamide demonstrated compelling efficacy across multiple endpoints: With a median follow up of 4.9 months, landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, are consistent with the competitor PRC2 inhibitor currently in Phase 3 in post-abiraterone mCRPC patients and superior to available standard-of-care therapies, including Xtandi, Jevtana, Taxotere, and Pluvicto. For reference, the 5-month landmark rPFS for these approved therapies ranges from approximately 60% to 75%. 47% of patients (7/15) achieved a PSA50 response, with 33% (5/15) confirmed. Impressive ctDNA reductions observed across a range of AR mutations, with 71% of patients (10/14) achieving >50% ctDNA reduction. The company expects to initiate the Himalayas-1 global Phase 3 registrational trial in mCRPC patients previously treated with abiraterone in the first half of 2026. This proposed trial will enroll approximately 600 patients from over 250 sites in over 20 countries, randomized 1:1 to receive the RP3D of 400 mg QD rinzimetostat in combination with darolutamide versus physician’s choice of an AR inhibitor or chemotherapy. The primary endpoint is rPFS, the key secondary endpoint is overall survival, and additional secondary endpoints include PSA response rate, objective response rate and patient reported outcomes. In the US, the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000, with an estimated addressable market of greater than $3,500 million and total global addressable market of $7,000 million. This market lacks oral, well-tolerated therapies with meaningful efficacy. Rinzimetostat 400 mg QD plus darolutamide is currently being evaluated in a food effect cohort. Thus far, there does not appear to be a significant food effect, consistent with previous single agent studies. Furthermore, as of March 6, 2026, early efficacy and safety are consistent with fasted results, with two confirmed PSA50 responses and one confirmed PSA90 response in the first five patients dosed, and all TRAEs reported being Grade 1 with a single Grade 2 TRAE. The company is also evaluating additional prostate cancer populations for future potential Phase 3 trials in mCRPC and mCSPC. Early data from rinzimetostat in 19 patients with mCRPC previously treated with AR inhibitors demonstrated compelling landmark rPFS rates of 93%, 85%, and 85% at 3, 4, and 5 months, respectively, with a median follow-up of 4.8 months. Rinzimetostat is being evaluated in a Phase 1b dose optimization trial in combination with ERLEADA (apalutamide), Johnson & Johnson’s AR inhibitor, and NUBEQA (darolutamide), Bayer’s AR inhibitor, in patients with mCRPC. Patients are eligible if they have received prior treatment with an ARPI and up to one prior chemotherapy. The primary objective of the trial is to determine the RP3D, and additional objectives include safety, tolerability, pharmacokinetics, and preliminary clinical activity.

Seeking Alpha • Oct 14

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ORIC is well-capitalized with Q2 cash position of $237.8M and valuation appears overly pessimistic at EV of negative $80M. ORIC is a Speculative Buy. Key risks include disappointing data for phase 1 readouts 1H 23, delays in the clinic and heavy competition in certain areas. Shares of ORIC Pharmaceuticals (ORIC) have fallen by over 80% since upsized IPO was priced at $16 in April of 2020. So far in 2022, share price has also experienced a dismal 80% decline. Back in March I sold my remaining shares for a 68% loss at $4.50 (still 50% higher than where they currently trade). However, I did highlight conviction-sized insider buying and reminded readers that I planned to revisit in a couple quarters when 2023 readouts were closer. As time has passed, I decided to check back in on the story and found the valuation to be incredibly pessimistic ($120M market capitalization versus estimated Q3 cash position of just over $200M). In other words, Mr. Market is stating that ORIC, with 3 clinical-stage programs in early phase 1b studies, is worth NEGATIVE $80M. These are not merely "me-too" assets, as their EGFR/HER2 exon-20 program is brain penetrant (can address CNS-metastases where approved agents lack activity). Likewise, the PRC2 program is targeting the EED subunit whereas predecessors have opted for the EZH2 subunit (plagued by tolerability issues) and management noted that certain subpopulations in prostate cancer could allow for accelerated approval should data warrant. The above to say, with the usual caveats, that I think we should dig deeper as the company would seem to be worth more than NEGATIVE $80M. Chart Finviz Figure 1: ORIC weekly chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, the decline from highs above $40 to current $3 share price is quite sickening (appears as if the company has "flat-lined" and is a shell of its former self). Despite looking like a shell company, there is still a lot going on under the hood (three phase 1 studies with readouts coming 1H 23) and so my initial suggestion for risk-tolerant investors would be to accumulate a small to modestly sized position at current levels ahead of these events. Given the current macro environment and headwinds to both risk assets as well as biotech sector, purchases could be spaced out over a period of months (or even quarters) instead of all at once. Overview Founded in 2014 with headquarters in San Francisco (78 employees), ORIC Pharma currently sports enterprise value of ~NEGATIVE $80M and estimated Q3 cash position of $200M providing them operational runway into 2H 2024. Here are my notes from September's Wainwright webcast which provides an excellent overview of current operations: ORIC= Overcoming Resistance in Cancer and encompasses their mission statement. Pipeline is broad and consists of potential first-in-class drug candidates and they have 3 ongoing phase 1b single-agent studies focused on validated targets followed by a pipeline of preclinical programs (both internally sourced as well as via external business development). They ended Q2 with $238M in cash with expected operational runway into 2H 24 (over a year after 3 data readouts expected in the first half of 2023). Corporate website Figure 2: Pipeline (Source: corporate website) Leadership team is highly experienced, starting with preclinical research discovery capabilities led by CSO and team that previously worked together at Genentech. They also possess full development, clinical and regulatory capabilities led by CMO and team that worked together previously at Ignyta and Aragon. Finally, they have extensive business development and strategic inlicensing capabilities via a team that worked together previously at Medivation and Ignyta. Successful oncology business models of the past several years tended to focus on building pipeline via internal discovery efforts or via business development. However, ORIC has been able to take a "source agnostic" approach to building the pipeline where the best molecule wins (whether internally developed or externally sourced). ORIC-533 is an oral bioavailable CD73 inhibitor discovered internally, whereas ORIC-114 was sourced from South Korean company Voronoi in October of 2020 and ORIC-944 from Mirati Therapeutics in July of 2020. They have 3 ongoing phase 1b studies. Bar is set high for differentiation versus competitors. Lastly, newest program is first-in-class PLK4 inhibitor in lead optimization stage. Starting with ORIC-533, they believe the molecule is differentiated on two fronts (both preclinically as well as via clinical development plan as a single agent in multiple myeloma). Preclinically versus other small and large molecule inhibitors of CD73 (as well as A2A receptor programs), ORIC-533 showed higher potency in multiple models. Also, 533 differentiates in a high adenosine or high AMP environment as well (important given high levels of adenosine typically seen in tumor microenvironment). For multiple myeloma, last year they showed a variety of preclinical results supporting potential as a single agent followed by combination trials pending single agent activity. Key takeaway from data presented last year (ex vivo autologous patient level) was that ORIC-533 achieved 40% lysis in these models (compared favorably to other approved agents in same models like lenalidomide and bortezomib). In the current phase 1 study they are enrolling late-line MM patients (triple and quad-refractory) starting as single agent. If there is even modest activity (sounds like the bar is not being set high), they'd move into multiple combination cohorts. As far as they know, ORIC-533 is the only CD73 inhibitor being tested as a single agent in multiple myeloma. Wainwright webcast Figure 3: Activity of ORIC-533 in MM comparable to standard of care therapies (Source: Wainwright presentation) Moving on to ORIC-114, this is a brain-penetrant EGFR/HER2 exon-20 program. Management prioritized finding a molecule selective for exon-20 insertion mutations over wild type (been a challenge for other players in the field). Second, they wanted to see CNS activity given prevalence of CNS metastases in this population. This molecule was specifically optimized across selectivity and brain penetration (exquisitely clean). Two currently approved agents for exon-20 have tolerability issues as well as lack of CNS activity. For ORIC-144, potent tumor regression has been observed in multiple non small cell lung cancer EGFR insertion models without significant weight loss. Head-to-head preclinical studies were also performed and 144 compared favorably in terms of efficacy and selectivity/signs of potential toxicities. Wainwright webcast Figure 4: In vivo efficacy for ORIC-144 compares favorably to competitors (Source: Wainwright presentation) The most important thing to highlight is CNS activity, as leading agents don't address CNS mets (35% to 40% of these patients develop CNS mets). In vivo data versus TAK-788 and osimertinib (clinically active CNS compound) showed superiority for ORIC-144. HER2 is another indication of interest for ORIC-144, and benchmark data versus Seagen's (SGEN) HER2 inhibitor tucatinib demonstrated antitumor activity in intracranial HER2+ breast cancer model (outperforming tucatinib). This is important as 50% of HER2+ breast cancer patients develop brain metastases. Phase 1b study is enrolling patients with advanced solid tumors who have either EGFR or HER2 exon-20 alterations or HER2 amplification or overexpression. Unlike competitor phase 1 studies, they are allowing patients with active CNS mets (treated or untreated but asymptomatic). CEO notes that amivantamab from JNJ is a great drug, but the big difference is again they are a large molecule and excluding patients with CNS mets. Wainwright webcast Figure 5: Superior efficacy for ORIC-144 in intracranial EGFR mutant models (Source: Wainwright presentation) Lastly, for allosteric PRC2 inhibitor ORIC-944, CEO notes that the PRC2 complex is a validated target with approved agents for epithelial sarcoma and follicular lymphoma. There are two druggable subunits for this complex, with most companies approaching it via EZH2 (associated with poor tolerability or PK limitations). There is only one other EED inhibitor in oncology (MAK683 from Novartis). Work done by Mirati comparing ORIC-944 to tazmetostat in DLBCL shows the former outperforming the latter by a wide margin. In androgen-resistant prostate cancer models, ORIC-944 showed good tumor growth inhibition (79% to 86% whereas competitors have seen 40% to 45% TGI). Per CEO, phase 1 study is progressing well (enrolling metastatic prostate cancer patients that have failed one or more AR modulators and up to 2 bouts of chemotherapy). These are later line patients lacking great options available, and goal is looking at safety, PK and selection of recommended phase 2 dose (sounds like they are expecting less in terms of early activity). Interestingly, they aim to see subsets of patients or potential biomarkers that would allow for accelerated approval in certain (smaller but still sizeable) populations. Wainwright webcast Figure 6: Strong single agent activity observed for ORIC-944, significantly better than blockbuster drug enzalutamide (Source: Wainwright presentation) PLK4 inhibitor program is in lead optimization, with the rationale being that cells with TRIM37 amplification require PLK4 function for growth and survival. TRIM37 amplification occurs in 20% of breast cancer and 50% of neuroblastoma and has been associated with early relapse and poor prognosis. This represents a synthetic lethality approach. Other Information For the second quarter of 2022, the company reported cash and equivalents of $237.8M contrasting favorably to R&D expenses of $13.8M and G&A expenses of $6.9M. Management is guiding for operational runway into 2H 2024, which seems reasonable to my eyes. Accumulated deficit to date per 10-K filing is around $245M, a reasonable figure for a company founded in 2014. As for competition, I do think it's important to keep an eye on Novartis' PRC2 inhibitor MAK683. Per clinical trials gov website, DLBCL seems to be the lead indication on deck for them. However, the study design allows for evaluation in other advanced malignancies such as nasopharyngeal carcinoma ((NPC)), gastric cancer, prostate cancer or other advanced solid tumors for whom no further effective standard treatment is available. Thus, any positive data reported here would likely spark a sympathy move in shares of ORIC as well. ORIC's PRC2 inhibitor to my eyes could be its crown jewel asset out of the 3 drug candidates currently in human studies. As mentioned above, there are certain populations they could potentially pursue accelerated approval via use of biomarkers such as H3K27 trimethylation. In EGFR exon 20, I am most familiar with Cullinan Oncology's (CGEM) CLN-081, which was the recipient of co-develop deal with Taiho Oncology for $275M upfront (allows for 50/50 US share of profits). Contrast the size of the upfront payment alone to ORIC's negative EV. Core Biotech holding Blueprint Medicines (BPMC) also scooped up LNG-451 in 2021 for $250M upfront payment (this drug candidate is highly brain penetrant as well). I imagine that ORIC will have a hard time going up against such larger players including Takeda, but again showing early monotherapy activity in patients with brain metastases would still positively impact share price and sentiment which are at all-time lows. As for ORIC-533, I remain highly skeptical of the inroads they can make in the highly crowded field of multiple myeloma given the impressive efficacy of approved CAR-T treatments not to mention next-generation cell therapy pioneers behind them (see my previous piece on Arcellx). As for institutional investors of note, EcoR1 Capital owns an 8.8% stake and has been adding to its position. String of insider purchases back in Q2 of this year was also encouraging, with CEO Jacob Chacko buying over $2.6M worth of shares.

Ratio de couverture des intérêts	n/a
Argent liquide	US$281.93m
Fonds propres	US$415.56m
Total du passif	US$21.21m
Total des actifs	US$436.76m

Données	Dernière mise à jour (heure UTC)
Analyse de l'entreprise	2026/06/18 11:45
Cours de l'action en fin de journée	2026/06/18 00:00
Les revenus	2026/03/31
Revenus annuels	2025/12/31

Paquet	Données	Cadre temporel	Exemple de source américaine ^*
Finances de l'entreprise	10 ans	Compte de résultat Tableau des flux de trésorerie Bilan	Formulaire 10-K de la SEC Formulaire 10-Q de la SEC
Estimations consensuelles des analystes	+3 ans	Prévisions financières Objectifs de prix des analystes	Rapports de recherche des analystes Blue Matrix
Prix du marché	30 ans	Cours des actions Dividendes, scissions et actions	Données de marché ICE Formulaire S-1 de la SEC
Propriété	10 ans	Actionnaires principaux Délits d'initiés	Formulaire 4 de la SEC Formulaire 13D de la SEC
Gestion	10 ans	L'équipe dirigeante Conseil d'administration	Formulaire 10-K de la SEC Formulaire SEC DEF 14A
Principaux développements	10 ans	Annonces de l'entreprise	Formulaire 8-K de la SEC

Analyste	Institution
Colleen Kusy	Baird
Prakhar Agrawal	Cantor Fitzgerald & Co.
Yigal Nochomovitz	Citigroup Inc

ORIC Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Invest In Growth?

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Recent updates

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026

ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings

ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile

Oric Pharmaceuticals Reports Combination Dose Optimization Data From Phase 1b Trial Of Rinzimetostat In Patients With Metastatic Castration Resistant Prostate Cancer

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside

New major risk - Revenue and earnings growth

President notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Price target increased by 9.0% to US$19.92

ORIC Pharmaceuticals, Inc. Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

ORIC Pharmaceuticals, Inc. Announces Publication in Cancer Research on the Discovery and Development of Enozertinib

ORIC Pharmaceuticals, Inc. Presents Preclinical Data At the Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-In-Class Potential of ORIC-944 to Treat Patients with Prostate Cancer and Other Solid Tumors

Chief Financial Officer notifies of intention to sell stock

President notifies of intention to sell stock

Oric Pharmaceuticals, Inc. Appoints Kevin Brodbeck as Chief Technical Officer

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Chief Financial Officer notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. announced that it has received $124.999983 million in funding from a group of investors

Oric Pharmaceuticals, Inc. Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2025

ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Invest In Growth?

Independent Director exercised options to buy US$383k worth of stock.

ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs

New major risk - Revenue and earnings growth

ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data

New minor risk - Share price stability

ORIC Pharmaceuticals, Inc. Provides Early Phase 1b Combination Data for ORIC-944

President notifies of intention to sell stock

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Insufficient new directors

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

New minor risk - Share price stability

ORIC Pharmaceuticals, Inc. Appoints Keith Lui as Senior Vice President of Commercial and Medical Affairs

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

Independent Director exercised options to buy US$181k worth of stock.

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Price target increased by 9.3% to US$19.13

ORIC Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

President notifies of intention to sell stock

Price target increased by 7.7% to US$17.50

President notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944

President exercised options and sold US$125k worth of stock

ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Price target increased by 12% to US$15.14

President notifies of intention to sell stock

President notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. announced that it has received $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals, Inc. announced that it expects to receive $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?